Screening of LDLR, APOB and TNNI3 Genes in Cardiovascular Patients in the Population of Indian Origin
DOI:
https://doi.org/10.61841/wd9qvy27Keywords:
Cardiac disorders, splicing, APOB, LDLRAbstract
Background: CVD accounts for 31% of mortality, the majority of this in the form of CHD and cerebrovascular accident, the majority of this in the form of CHD and cerebrovascular accident.
Methods: Institutional Human Ethics Committee approval was taken for the current study from Bharti Hospital and Savitribai Phule Pune University. DNA was extracted from whole blood, and PCR conditions were optimized for all exons. SSCP was done for screening of variations in all the exons of the APOB, LDLR, and TNNI3 genes. Samples showing abnormal band shifts with respect to control were Sanger sequenced for confirmation of variation. Biochemical estimations were done by commercially available kits.
Results: SSCP analysis reveals a band shift in exon 05 of the APOB gene with respect to control samples on 8% gel concentration in proband 16, while other exons of the APOB gene did not show any band shift with respect to control samples. T>G transversion at Chr. Location 55663368 of the intraonic variant was located in exon 08 of proband 13 by screening of all exons of the TNNI3 gene. Sequences revealed. Patient showing G/A variation shows LVEF of 47%, while CVD patients without variation show 43%. The level of NO in control was lower than the MI level and IHD level, but MI patients show the highest level of NO.
Conclusion: A reported silent mutation was found in the intronic region without impact on splicing. This variation did not show a profound impact on physiological complication as compared to mutation-negative probands
Downloads
References
[1] Aggerbeck LP, Bouma ME, Eisenberg C, Munck A, Hermier M, Schmitz J, Gay G, Rader DJ, Gregg RE.
Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science.
1992 Nov 6; 258(5084):999-1001.
[2] Bredt DS, Snyder SH. Nitric oxide: a physiologic messenger molecule. Annual reviewof biochemistry.
1994 Jul; 63(1):175-95.
[3] Chahine RA, Eber LM, Kattus AA. Interpretation of the serum enzyme changes following
cardiaccatheterization and coronary angiography. American heart journal. 1974 Feb 1; 87(2):170-4.
[4] Elovson J, Chatterton JE, Bell GT, Schumaker VN, Reuben MA, Puppione DL, Reeve JR, Young NL.
Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. Journal of lipid
research. 1988 Nov 1; 29(11):1461-73.
[5] Finkelshtein D, Werman A, Novick D, Barak S, Rubinstein M. LDL receptor and its family members serve
as the cellular receptors for vesicular stomatitis virus. Proceedings of the National Academy of Sciences.
2013 Apr 30; 110 (18):7306-11.
[6] Global Burden of Disease (GBD), 1990.
[7] Goyal A, Yusuf S. The burden of cardiovascular disease in the Indian subcontinent. Indian J Med Res.
2006 Sep 1; 124(3):235-44.
[8] GRANGE RW, Isotani EI, LAU KS, KAMM KE, HUANG PL, STULL JT. Nitric oxidecontributes to
vascular smooth muscle relaxation in contracting fast-twitch muscles. Physiologicalgenomics. 2001 Feb 7;
5(1):35-44.
[9] Gupta R, Misra A, Vikram NK, Kondal D, Gupta SS, Agrawal A,Pandey RM. Younger age of escalation of
cardiovascular risk factorsin Asian Indian subjects. BMC Cardiovascular Disorder. 2009; 9:28.
[10] Harrison DC, WEXLER L, MATLOFF H. Serum enzymes following coronary and other forms of cardiac
angiography. In Circulation 1972 Jan 1 (Vol. 46, No. 4, p. 21.
[11] Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, Pencina MJ, Schoonmaker C,
Wilson PW, D’Agostino RB, Vasan RS. Clinical utility of different lipid measures for prediction of
coronary heart disease in men and women. Jama. 2007 Aug 15; 298(7):776-85.
[12] Joshi P, Islam S, Pais P, Reddy S, Dorairaj P, Kazmi K, Pandey MR, Haque S, Mendis S, Rangarajan S,
Yusuf S. Risk factors for early myocardial infarction in South Asians compared with individuals in other
countries. Jama. 2007 Jan 17; 297(3):286-94.
[13] Kane JP. Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. The
metabolic and molecular basis of inherited disease. 1995.
[14] Kurniawan ND, Aliabadizadeh K, Brereton IM, Kroon PA, Smith R. NMR structure and backbone
dynamics of a concatemer of epidermal growth factor homology modules of the human low-density
lipoprotein receptor. J Mol Biol. 2001: 311(2): 341-56.
[15] Leren TP. Sorting an LDL receptor with bound PCSK9 to intracellular degradation. Atherosclerosis. 2014
Nov 1; 237(1):76-81.
[16] McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, Steyn K, Sanderson JE, Hasani
M, Volkova E, Kazmi K. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction
in 52 countries (the INTERHEART study): a case-control study. The Lancet. 2008 Jul 19; 372(9634):224-
33.
[17] Mendis S, Puska P, Norrving B, World Health Organization. Global atlas on cardiovascular disease
prevention and control. Geneva: World Health Organization; 2011.
[18] O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, Rangarajan S, Islam S, Pais P,
McQueen MJ, Mondo C. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries
(the INTERSTROKE study): a case-control study. The Lancet. 2010 Jul 10; 376(9735):112-23.
[19] Pierre AC, Cantin B, Dagenais GR, Després JP, Lamarche B. Apolipoprotein-B, low-density lipoprotein
cholesterol, and the long-term risk of coronary heart disease in men. The American journal of cardiology.
2006 Apr 1; 97(7):997-1001.
[20] Poppe KK. What is normal left ventricular ejection fraction? A global individual person data meta-analysis
of the distribution across ethnicity, gender and age. European Heart Journal. 2013 Aug 1; 34.
[21] Russell DW, Brown MS, Goldstein JL. Different combinations of cysteine-rich repeats mediate binding of
low density lipoprotein receptor to two different proteins. Journal of Biological Chemistry. 1989 Dec 25;
264(36):21682-8.
[22] Schonfeld G. Familial hypobetalipoproteinemia a review. Journal of lipid research. 2003 May 1; 44(5):878-
83.
[23] Talmud PJ, Hawe E, Miller GJ, Humphries SE. Nonfasting apolipoprotein B and triglyceride levels as a
useful predictor of coronary heart disease risk in middle-aged UK men. Arteriosclerosis, thrombosis, and
vascular biology. 2002 Nov 1; 22(11):1918-23.
[24] Verdecchia P, Angeli F, Gattobigio R, Sardone M, Porcellati C. Asymptomatic left ventricular systolic
dysfunction in essential hypertension: prevalence, determinants, and prognostic value. Hypertension. 2005
Mar 1; 45(3):412-8.
[25] Whitfield AJ, Marais AD, Robertson K, Barrett PH, Bockxmeer FV, Burnett JR. Four novel mutations in
APOB causing heterozygous and homozygous familial hypobetalipoproteinemia. Human mutation. 2003
Aug; 22(2):178.
[26] Xavier D, Pais P, Devereaux PJ, Xie C, Prabhakaran D, Reddy KS, Gupta R, Joshi P, Kerkar P,
Thanikachalam S, Haridas KK. Treatment and outcomes of acute coronary syndromes in India (CREATE):
a prospective analysis of registry data. The Lancet. 2008 Apr 26; 371(9622):1435-42.
[27] Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J,
Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52
countries (the INTERHEART study): case-control study. The lancet. 2004 Sep 11; 364(9438):937-52.
[28] Yusuf S, Rangarajan S, Teo K, Islam S, Li W, Liu L, Bo J, Lou Q, Lu F, LiuT, Yu L, Zhang S, Mony P,
Swaminathan S, Mohan V, Gupta R, Kumar R,Vijayakumar K, Lear S, Anand S, Wielgosz A, Diaz R,
Avezum A, Lopez Jaramillo P,Lanas Yusoff K, Ismail N, Iqbal R, Rahman O, Rosengren A, Yusufali A,
Kelishadi R,Kruger A, Puoane T, Szuba A, Chifamba J, Oguz A, McQueen M, McKee M, DagenaisG;
PURE Investigators. Cardiovascular risk and events in 17 low-, middle-, and high income countries. N Engl
J Med. 2014; 371:818–827.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
